To further clarify the role of FTO, LIN892, LIN989, PROX1-AS1 and SENCR in drug resistance, we obtained CML PB cells from patients after nilotinib or imatinib therapy. The gene discussed is FTO; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.